Veterinary Services Memoranda
Last Modified: May 03, 2024
| Number | Title | Issue Date |
|---|---|---|
| 800.50 (167.33 KB) | Basic License Requirements and Guidelines for Submission of Materials in Support of Licensure | April 2, 2018 |
| 800.51 | Additives in Administered Animal Biological Products | August 17, 2018 |
| 800.52 | Export Certificates and Certificates of Licensing and Inspection for Animal Biological Products | December 9, 2021 |
| 800.53 | Serial Release of Licensed Biological Products | July 15, 2020 |
| 800.54 | Guidelines for the Preparation and Review of Labeling Materials | September 17, 2018 |
| 800.55 | Concurrent and Confirmatory Tests of Market Serials | February 17, 1986 |
| 800.56 | Disposal of Unsatisfactory and Undesirable Materials | March 12, 2008 |
| 800.57 | Market Suspensions and Post Marketing Temperature Deviations | June 11, 2018 |
| 800.58 | Sublicensing of Veterinary Biological Products | October 18, 2007 |
| 800.59 | Veterinary Biological Product Samples | July 20, 2016 |
| 800.60 | Biological Products Returned to Licensed or Permitted Establishments | March 11, 2008 |
| 800.61 | Split Manufacturing of Veterinary Biological Products | October 21, 1999 |
| 800.62 | Relabeling, Rebottling, and Reprocessing Veterinary Biological Products | December 22, 1999 |
| 800.63 | Personnel at Licensed Establishments | December 19, 2016 |
| 800.64 | Preparation of Experimental Products at Licensed Establishments | March 14, 2012 |
| 800.65 | Eggs and Chickens for Production of Veterinary Biological Products | May 03, 2016 |
| 800.66 | Freedom of Information Act Requests Involving Veterinary Biological Products | October 21, 1999 |
| 800.67 | Shipment of Experimental Veterinary Biological Products | November 25, 2022 |
| 800.68 | Retired | -- |
| 800.69 | Guidelines for Autogenous Biologics | November 22, 2021 |
| 800.70 | Rabies Vaccine Immunogenicity Test Protocols | April 27, 2000 |
| 800.73 | Basic Licensing Requirements and Guidelines for Diagnostic Products | May 1, 2024 |
| 800.74 | Preparation and Distribution of Sterile Diluents | November 4, 1999 |
| 800.75 | Reissuance of Product Licenses for Products Under Conditional Licenses | July 14, 2022 |
| 800.77 | Unsatisfactory Product Stability | July 14, 1986 |
| 800.78 | Preparation and Submission of Facilities Documents | September 24, 2019 |
| 800.79 | Submission of Host Animal Serum Samples for In Vitro Potency Tests | March 20, 2013 |
| 800.81 | Chicken Bursa Origin Bursal Disease Vaccines | March 30, 2001 |
| 800.83 | Export of Serials Before Completion of Serial Release Testing | November 14, 2011 |
| 800.84 | Canceled. Superseded by VSM 800.50 (167.33 KB) | -- |
| 800.85 | Avian Influenza Vaccines | July 13, 2020 |
| 800.86 | Exemption from Mycoplasma Testing in Accordance with Title 9, Code of Federal Regulations, Part 113.200 (c) (3) | November 4, 1999 |
| 800.87 | Guidelines for Licensing Establishments with Separated Premises | May 13, 2005 |
| 800.88 | Testing for Reticuloendotheliosis Virus Contamination | August 23, 1999 |
| 800.89 | Chicken Anemia Virus | December 22, 1999 |
| 800.90 | Retired. Incorporated into VSM 800.112 (88.47 KB) | -- |
| 800.91 | Inspection of U.S. Veterinary Biologics Licensed and Permitted Establishments | December 8, 2020 |
| 800.92 | Retired. Incorporated into VSM 800.206 (495.98 KB) and 800.53 | -- |
| 800.94 | Food and Drug Administration's Export Reform and Enhancement Act of 1996 | May 10, 2011 |
| 800.95 | GB Texas Newcastle Disease Challenge Virus | September 2, 2015 |
| 800.97 | Standard Reference Preparations, Test Reagents, and Seed Cultures for Laboratory Test Reagents | June 12, 2014 |
| 800.98 | Advertising and Promotional Materials | July 25, 2008 |
| 800.99 | Guidelines for Using In Vitro Relative Potency Tests to Determine the Antigen Content of Inactivated Bovine Rhinotracheitis Vaccine | April 26, 2001 |
| 800.100 | Exemption from Using Heat or Ionizing Radiation to Treat Equine Plasma Used in Manufacturing Plasma Products for Oral or Parenteral Administration to Horses Under 9 CFR 113.450(e)(1) and Exemption from the Mouse Safety Test Under 9 CFR 113.450 (i) | July 29, 2002 |
| 800.101 | U.S. Veterinary Biological Product Permits for Distribution and Sale | November 1, 2016 |
| 800.102 | Exemption from Leptospira Bacterin Testing Under 9 CFR 113.101-104 and the Associated References and Studies | December 12, 2013 |
| 800.103 | Reissuance of Product Licenses for Autogenous Products and Guidance Concerning Restrictions on the Production and Use of Veterinary Biologics | July 18, 2018 |
| 800.104 | In Vitro Serial Release Potency Test for Completed Product Containing Clostridium chauvoei | December 13, 2018 |
| 800.106 | Exemption to Sterility Test Requirement for Allergenic Extract Prescription Product | February 16, 2022 |
| 800.107 | Policy for Changing Cells and Cell Substrates of Licensed Vaccines | November 25, 2002 |
| 800.108 | Inventory and Disposition Records | January 15, 2003 |
| 800.109 | Master Seed and Master Cell Stock Testing Report Submission | May 26, 2004 |
| 800.110 | Label Warnings Concerning Bovine Rhinotracheitis Vaccine, Modified Live Virus, and Bovine Virus Diarrhea Vaccine, Modified Live Virus, for Pregnant Cows or Calves Nursing Pregnant Cows | June 30, 2017 |
| 800.111 | Viral Strain Changes in Equine Influenza and Swine Influenza Vaccines (Killed Virus) | September 19, 2007 |
| 800.112 | Guidelines for Validation of In Vitro Potency Assays | April 10, 2015 |
| 800.113 | Production, Testing and Storage of Master Seed and Master Cell Stocks at Alternate Locations | September 17, 2008 |
| 800.114 | Alternative Test Procedure for Tuberculin, PPD Bovis, Intradermic | April 13, 2012 |
| 800.115 | Potency and Safety Testing by Unlicensed Facilities | April 11, 2019 |
| 800.116 | Target Animal Safety Testing Exemption | August 14, 2017 |
| 800.117 | Guidance for Inactivation Studies | August 12, 2013 |
| 800.119 | Exemptions to title 9, Code of Federal Regulations (9 CFR), Part 113.28, Detection of Mycoplasma Contamination | March 19, 2014 |
| 800.120 | Dilution of Preservative Screening for Sterility Testing of Veterinary Biologics | June 27, 2014 |
| 800.121 | Autologous Therapeutic Biologics | June 21, 2017 |
| 800.122 | Electronic Recordkeeping and Compliance with 9 CFR Part 116 | November 3, 2017 |
| 800.123 | Coccidiosis Vaccines | November 8, 2018 |
| 800.124 | Guidelines for Potency Specifications of Biological Products Administered to Animals | October 2, 2020 |
| 800.125 | Preparation and Submission of Adverse Event Reports for Biological Products by Licensees and Permittees | August 17, 2020 |
| 800.126 | Efficacy and Safety Studies for Cancer Immunotherapeutics | September 2, 2020 |
| 800.127 | Guidelines for Conducting Product Stability Studies | March 29, 2022 |
| 800.200 | General Licensing Considerations: Study Practices and Documentation | June 12, 2014 |
| 800.201 | General Licensing Considerations: Backpassage Studies | January 25, 2018 |
| 800.202 | General Licensing Considerations: Efficacy Studies | October 26, 2016 |
| 800.203 | General Licensing Considerations: Compatibility of Components | January 16, 2007 |
| 800.204 | General Licensing Considerations: Field Safety Studies | January 25, 2018 |
| 800.205 | General Licensing Considerations: Biotechnology-derived Veterinary Biologics Categories I, II, and III | May 28, 2003 |
| 800.206 | General Licensing Considerations: Preparing Outlines of Production for Vaccines, Bacterins, Antigens, and Toxoids and Diagnostic Test Kits | November 13, 2018 |
| 800.207 | General Licensing Considerations: Target Animal Safety (TAS) Studies Prior to Product Licensure - VICH Guideline 44 | July 6, 2010 |
| 800.208 | Special Labels for Product for Export | October 21, 2010 |
| 800.209 | Bovine Corona Virus and Rotavirus Master Reference Qualification by Colostral Antibody Titers | December 8, 2010 |
| 800.210 | Manufacturing Deviations Identified Prior to Marketing Release | May 31, 2018 |
| 800.211 | Guidance for Master Reference Qualification, Requalification, Dating, and Monitoring | February 8, 2023 |
| 800.212 | Licensing Considerations: Vaccine Claims for Protection of the Fetus Against Bovine Virus Diarrhea Virus | November 14, 2011 |
| 800.213 | Licensing Guidelines for Production Platform-Based, Non-Replicating, Nonviable Products | March 12, 2018 |
| 800.214 | Prescription Platform Product Biologics | March 12, 2018 |
| 800.215 | Guidelines Regarding the Revision to Animal and Plant Health Inspection Service (APHIS) Implementing Procedures for the National Environmental Policy Act (NEPA) | January 31, 2019 |
| 800.300 | Stability Testing of New Biotechnological/Biological Veterinary Medicinal Products | July 26, 2001 |
| 800.301 | Good Clinical Practices (See CVB Notice 01-11 (556.14 KB) for additional guidance regarding application of this VS Memo) | July 26, 2001 |